go back

Ovarian Cancer Targeted Drug Response Test

New Jersey rates for HCPCS 0325U

Helps choose treatment for ovarian cancer by growing the patient's own cancer cells in the laboratory and exposing them to four targeted drugs, niraparib, olaparib, rucaparib and veliparib, to see which the cells respond to. The result is reported as a classification of likely response. A companion test does the same with chemotherapy drugs instead.

Rates data updated October 2026.

How much rates vary

Facilitymedian $18,621 · 10th to 90th $8,710 to $28,840Professionalmedian $776 · 10th to 90th $776 to $776
$200$1K$5K$20Kfacility $18,621professional $776

Distribution of negotiated rates across all payers (price axis is log-scale). Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
Cigna
Setting
Professional
Modifier
None
Typical Low
$1,348.96
Median
$1,348.96
Typical High
$1,698.24
Horizon BCBS
Setting
Facility
Modifier
None
Typical Low
$8,709.64
Median
$18,620.87
Typical High
$28,840.32
Horizon BCBS
Setting
Professional
Modifier
None
Typical Low
$776.25
Median
$776.25
Typical High
$776.25